Traunecker W
Department of Pharmacology, Boehringer Ingelheim KG, Ingelheim/Rheir, Fed. Rep. of Germany.
Arzneimittelforschung. 1988 Nov;38(11):1623-4.
A marked and long-lasting bronchospasmolytic effect without any cardiovascular side effects has been demonstrated in anaesthetized dogs following inhalation of 0.1 mg oxitropium bromide, with glucose as vehicle, administered as powder in powder inhaler capsules.
在麻醉犬吸入以葡萄糖为载体、以粉末吸入剂胶囊形式给药的0.1毫克氧托溴铵后,已证明其具有显著且持久的支气管解痉作用,且无任何心血管副作用。